此前，阿里巴巴已通过通义千问、蚂蚁阿福布局C端健康服务。高门槛、高专业性的严肃医疗场景应 用，则交由深耕医疗健康领域十余年的阿里健康承接。至此，阿里在医疗健康领域的AI布局已实 现"C+D"端的完整布局。 新浪科技讯 1月19日上午消息，阿里健康推出AI产品"氢离子"，现已完成内测并开放下载。 据悉，该产品已进入实际应用阶段，主要面向临床、科研领域的医生群体。据了解，"氢离子"主打"低 幻觉、高循证"核心能力，所有回答均有权威出处，支持一键溯源、直达信源，致力于打造医疗领域幻 觉率最低的AI助手。 此前，阿里健康财报中也曾透露，其自研医学大模型正在积极探索在严肃医疗领域的应用场景，致力增 强模型在临床决策、临床科研等关键环节的AI循证能力。此次，"氢离子"正是该模型能力的首个产品化 体现。 据参与内测的医生反馈，"氢离子"在循证问答、证据整合与分析总结等任务中表现出高度准确度，尤其 在临床、科研语境下的智能检索和中英文献研读方面，更贴合国内医生习惯。其产品逻辑与海外大热的 OpenEvidence相似，但在本地化体验上更具优势。 此前，阿里健康财报中也曾透露，其自研医学大模型正在积极探索在严肃医疗领域的应用场 ...

有业内人士指出，当前国内尚缺乏真正面向专业医生、以循证为基础的垂类AI工具。"氢离子"若能持续 验证其在临床与科研场景中的实用性与可靠性，则有望成为中国的OpenEvidence。 阿里健康旗下AI产品"氢离子"已完成内测并已开放下载。该产品面向临床、科研领域的医生群体，定位 是医生版"GPT"，这也是阿里健康自研医学大模型的首个落地应用。据悉，"氢离子"主打"低幻觉、高 循证"核心能力，所有回答均有权威出处，支持一键循证、直达信源，旨在打造医疗领域幻觉率最低的 AI助手。 多位参与内测的医生反馈，"氢离子"在循证问答、证据整合与分析总结等任务中表现出高度准确度，尤 其在临床、科研语境下的智能检索和中英文献研读方面，更贴合国内医生习惯。其产品逻辑与海外大热 的OpenEvidence相似，但在本地化体验上更具优势。 ...

据新华社电 1月18日，海南自由贸易港封关运作满月。记者走访海南各地发现，政策红利持续释放、商 旅活动人气旺盛、运输网络织密升级，开放发展呈现新气象。 政策红利加速释放 "一线"监管"零关税"货物7.5亿元 在位于三亚的海南海润珍珠股份有限公司，工匠们凝神屏息，借助显微镜，用精细镊子将珠宝稳稳嵌入 雕花珠托。具备珠宝生产全流程工艺的海润珍珠，是海南自贸港加工增值政策的直接受益者。其高附加 值加工产品可免关税内销，企业也借此从零售商转型为综合产业运营商。 1月以来，一些中外地方政府代表团、商会、高等院校等纷纷赴琼，洽谈合作、考察签约。据海口海关 统计，封关一个月来，海口海关共监管海南空港口岸进出境人员31.1万人次，同比增长48.8%。 "公司产品综合税率从52%降至26%左右，为研发腾出更多资金。"公司董事长张士忠说，眼下，公司正 忙于筹备一场珍珠竞价会，综合运用自贸港各项政策，可实现珍珠产品进口"零担保、无感监管、无复 运时限、可加工"等突破。 据海口海关统计，自2025年12月18日封关以来截至1月17日，海口海关在"一线"监管"零关税"货物7.5亿 元，在"二线"监管销往内地的加工增值免关税货物8586 ...

2、2026年国内财政与货币政策持续性可期，财政政策方面，预计2026年财政政策力度和2025年接近； 货币政策方面，大型银行仍有降准空间，预计2026年降息20BP左右、降准25BP～50BP。2026年A股资 金面中长线资金有望稳步入市，对市场形成支撑。在定期存款利率回落趋势下，居民储蓄有望从银行存 款中流出，转入理财与保险。2026年债券或仍难有长期趋势性机会，理财、险资最佳配置品种或仍为股 票。 3、海外方面，2026年美联储主席更替在即，海外宏观流动性有超预期宽松可能，在中期选举压力下， 特朗普继续对美联储施压，降息次数或超预期。增量资金支撑下，股市表现有望强于基本面。但目前市 场整体估值偏贵、海外二次通胀风险、科技公司泡沫担忧以及我国潜在贸易摩擦多边化问题，仍是主要 风险。同时，市场如果阶段性涨幅过大、速度过快，监管层面也有主动降速考虑。 4、配置策略：聚焦景气度与性价比。市场估值相对偏高，配置层面需要结合景气度与性价比综合考 虑。自上而下来看，消费、投资、地产依然偏弱，出口链相对有韧性。自下而上来看，产业趋势热点依 然在科技、有色、储能、电力设备出海，以及反内卷已经落地的化工板块。小票、成长、主 ...

Core Insights - The article discusses the recent advancements in AI applications within the healthcare sector, highlighting the shift from model capabilities to productization and integration into real medical workflows [3][32]. Group 1: OpenAI Developments - OpenAI launched ChatGPT Health on January 7, 2026, designed as a dedicated health experience within ChatGPT, focusing on aggregating health information from various sources while ensuring privacy and compliance [6][11]. - The acquisition of health tech company Torch for approximately $100 million aims to enhance the integration of lab results, medication information, and medical records into a cohesive product [11][13]. - ChatGPT Health supports connections to health applications like Apple Health and MyFitnessPal, emphasizing a shift towards data aggregation and traceability [8][13]. Group 2: Google's Initiatives - Google updated its MedGemma 1.5 and MedASR models on January 14, 2026, focusing on medical image understanding and voice transcription capabilities [14][20]. - MedGemma 1.5 is designed to interpret medical images, including complex scenarios, and can operate offline, which is crucial for deployment in various healthcare settings [17][20]. - MedASR aims to improve the transcription of medical voice recordings, addressing challenges related to specialized terminology and environmental noise [20][24]. Group 3: Anthropic's Strategy - Anthropic introduced Claude for Healthcare on January 11, 2026, positioning it as an enterprise-level assistant capable of integrating with real healthcare workflows while ensuring compliance [24][27]. - Claude can access key healthcare databases, facilitating tasks such as prior authorization reviews and claims processing, thereby reducing the time spent on fragmented information handling [31][27]. - The focus is on embedding Claude into existing systems rather than creating standalone solutions, addressing the need for structured data integration [35][31]. Group 4: Industry Trends - The actions of OpenAI, Google, and Anthropic indicate a collective focus on addressing existing healthcare demands rather than creating new ones, emphasizing the importance of data, tools, and process optimization [32][35]. - High-frequency healthcare needs are often related to understanding and organizing information rather than direct diagnosis, highlighting the potential for AI to streamline these processes [34][35]. - The key to healthcare innovation lies in making previously overlooked demands scalable, with AI providing solutions for long-standing inefficiencies in areas like health information management and medical record transcription [35][36].

Core Insights - The conference focused on the application of artificial intelligence (AI) in hospitals and the innovative directions for enhancing hospital operations through digital intelligence [1][8] - JD Health launched the 2.0 version of its "JD Zhuoyi" product, aimed at becoming a new growth engine for hospitals, having already served over 5 million patients since its initial launch in 2025 [2][3] Group 1: Product Launch and Features - JD Zhuoyi 2.0 integrates JD Health's "AI + Supply Chain" capabilities, providing a comprehensive management solution covering clinical nutrition, outpatient medication, and weight management [2][4] - The "AI + Clinical Nutrition" model focuses on nutritional assessment and intervention, utilizing a clinical nutrition model supported by extensive literature and real-world cases to enhance patient outcomes [3][4] - The "AI + Pharmacy Management" model aims to streamline the medication process through AI-assisted prescription review and a 24/7 online AI pharmacist, improving patient adherence and satisfaction [4] Group 2: Industry Collaboration and Insights - The conference featured discussions from various hospital leaders on the practical experiences and innovative measures in AI-enabled healthcare, contributing diverse perspectives to industry development [5][6] - JD Health signed strategic cooperation agreements with multiple partners to enhance the application of AI in healthcare, aiming to create a comprehensive supply chain for personalized nutrition solutions [7] - The successful hosting of the conference highlighted JD Health's technological strength in the medical AI field and established a platform for industry collaboration [8]

当脑瘤与语言中枢"贴面相邻"，切肿瘤还是保功能，曾是神经外科医生面临的艰难抉 择。如今，一项由华中科技大学同济医学院附属同济医院联合科技企业开展的突破性技术， 让这道难题有了全新解法：先短期植入硬膜下电极，把肿瘤边界和语言功能区画出来，再完 成脑肿瘤的精准切除。 1月16日，在同济医院神经外科病房里，长江日报记者看到，52岁的脑肿瘤患者张先生 在术后一周左右，已能够完整说出自己的名字。 8个月前，河南的张先生突发言语含糊、嗅觉减退、记忆力减退等情况，当地医院磁共 振检查提示，左侧额颞叶及岛叶区异常信号影并周围脑组织水肿，考虑肿瘤性病变。因病灶 紧邻语言中枢，传统手术极易造成永久性失语，手术风险极高。他多方辗转，来到同济医院 神经外科，找到舒凯教授。 "过去我们靠经验'绕开'功能区，如今脑机接口让功能地图'可视化'，切除边界一目了 然。"舒凯说，我国每年新增颅内占位性病变患者约40万例，其中20%位于功能区。传统手 术致残率高达15%—30%。此次手术成功验证了侵入式脑机接口在语言区病变中的安全性和 有效性，为脑部更多功能区疾病提供了标准化范式，有望为更多类似患者带来希望和治愈的 可能。 据悉，该技术获评武汉市 ...

上海润达医疗科技股份有限公司 关于2025年年度业绩预告的提示性 公告 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603108 证券简称：润达医疗 公告编号：临2026-010 转债代码：113588 转债简称：润达转债 公司指定的信息披露媒体为《中国证券报》、《上海证券报》、《证券日报》、《证券时报》及上海证 券交易所网站（www.sse.com.cn），有关公司信息均以公司在上述指定媒体披露信息为准。敬请广大投 资者理性投资，注意投资风险。 特此公告。 上海润达医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 经上海润达医疗科技股份有限公司（以下简称"公司"）财务部门初步核算，预计2025年年度归属于上市 公司股东的净利润为负值，公司2025年年度经营业绩将出现亏损。 公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工作，尽快披露2025 年年度业绩预告。最终财务数据请以公司正式披露的2025年年度报告为准。 董事会 2026年1月16日 ...

证券日报网讯1月16日，麦迪科技（603990）在互动平台回答投资者提问时表示，公司麻醉、重症、急 诊急救三大系统与多个大模型深度融合，并持续进行AI升级，已推出覆盖术前、术中、术后全流程的 麻醉AI助手，实现术前评估自动化、术中智能保障与专病库知识智能服务。重症产品支持云端与私有 化双部署，兼顾智能化与数据安全。急诊临床信息系统实现智能分级、辅助诊断、风险预警及电子病历 生成等功能突破。相关产品已与华为生态硬件以及其他的国产化硬件产品进行适配。同时，公司大力推 动康养机器人业务布局，自行开发的优麦AI语音助手交互系统已具备健康问答、情感陪伴、康养问诊 等功能，支持DeepSeek、豆包和千问等多种大模型接入。 ...

Group 1: Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.28%, the Hang Seng China Enterprises Index down by 0.52%, and the Hang Seng Tech Index decreasing by 1.35% [2] - The total market turnover was HKD 290.455 billion, with short selling amounting to HKD 35.078 billion, representing 13.62% of the total turnover [2] - Southbound capital saw a net outflow of HKD 1.515 billion, with Alibaba, Tencent, and SMIC being the most bought stocks, while China Mobile, Xiaomi, and CNOOC faced the most selling pressure [2] Group 2: Sector Performance - The AI healthcare and internet healthcare sectors faced adjustments, with notable declines in stocks such as Jingtai Holdings down 10.74% and Alibaba Health down 7.84% [2] - The OTA platform Trip.com Group saw a significant drop of 19.23% due to an investigation by the State Administration for Market Regulation for alleged monopolistic behavior [3] - The optical communication sector performed well, with stocks like Huiju Technology rising by 8.89% and Cambridge Technology increasing by 7.75% [3] Group 3: Monetary Policy and Economic Measures - The People's Bank of China announced a series of targeted monetary easing measures, including a structural interest rate cut of 0.25 percentage points, aimed at reducing financing costs in specific sectors [4] - A total of CNY 1 trillion was allocated to support private enterprises, with an additional CNY 500 billion specifically for small and medium-sized private companies [4] - The bank also increased the quota for technology innovation and technical transformation loans by CNY 400 billion, bringing the total to CNY 1.2 trillion [4] Group 4: Company Analysis - 361 Degrees - 361 Degrees reported better-than-expected performance with offline retail growth of approximately 10% for both its main brand and children's clothing [7] - The company continues to see strong growth in e-commerce, achieving high double-digit growth rates [7] - The launch of new products across various categories, including running, basketball, and outdoor gear, reflects the company's commitment to innovation and brand development [8] Group 5: Investment Outlook for 361 Degrees - The company is expected to benefit from the introduction of new store formats, which will contribute positively to its performance [9] - The forecast for EPS from 2025 to 2027 is projected at CNY 0.60, CNY 0.69, and CNY 0.76, respectively, with a target price of HKD 7.6 based on a 10x PE ratio for 2026 [9]